On August 16, 2021 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, reported that appointed Patrick Soon-Shiong, M.D., to the newly created role of Global Chief Scientific and Medical Officer, effective as of August 11, 2021 (Press release, ImmunityBio, AUG 16, 2021, View Source [SID1234586620]). In this additional role, Dr. Soon-Shiong will oversee the company’s global research and development programs and pipeline investments in support of its ambitious growth plans, which include bringing advanced technology to a broad global marketplace.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As both the founder of ImmunityBio and a visionary biotech innovator, Patrick’s expertise has always been an invaluable asset to the organization," said Richard Adcock, President and CEO of ImmunityBio. "We are grateful for his leadership and commitment to drive the scientific agenda of our business forward. His unwavering focus on advancing potential breakthrough therapies for cancer and infectious disease has already improved the quality of life for thousands of patients."
"My entire life’s work has been to discover and bring to market better treatments for cancer and other difficult-to-treat diseases, and thanks to incredible innovations over the last few years, we’re closer than ever to that goal," said Dr. Soon-Shiong. "Our growing knowledge of the immune system will serve as the foundation for the research priorities we’re setting at ImmunityBio. These priorities will guide our ongoing quest for life-saving and life-extending therapeutics, including a commitment to ensure they are available to people in underserved nations in Africa and elsewhere. That’s my goal and the goal of everyone on our highly experienced research, clinical development, and medical teams."